Intravenous methotrexate for treatment of interstitial pregnancy: a case report.

Abstract

BACKGROUND:

Ectopic pregnancy is the leading cause of first-trimester maternal death, accounting for 9% of pregnancy-related deaths. Interstitial (cornual) pregnancies represent 6% of all ectopics but account for a disproportionately higher mortality rate. Surgical management has been the treatment of choice for interstitial pregnancies. A very limited number of articles pre have explored the use of intravenous methotrexate to treat cornual pregnancy as a possible conservative first-line therapy in selected, hemodynamically stable patients.

CASE:

A patient with a confirmed interstitial pregnancy was treated with intravenous methotrexate. The patient's beta-hCG levels decreased to zero within 9 weeks.

CONCLUSION:

Intravenous methotrexate was used successfully in the treatment of an interstitial pregnancy without complications.

• Authors: Anthony Al-Khan, Roger Jones, Donald Fricchione, Joseph Apuzzio
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 49 Issue 2 Pg. 121-2 (Feb 2004) ISSN: 0024-7758 [Print] United States
• PMID: 15018441 (Publication Type: Case Reports, Journal Article)

Chemical References

• Abortifacient Agents, Nonsteroidal
• Chorionic Gonadotropin, beta Subunit, Human
• Folic Acid Antagonists
• Methotrexate

Topics

• Abortifacient Agents, Nonsteroidal (administration & dosage, adverse effects)
• Adult
• Chorionic Gonadotropin, beta Subunit, Human (blood)
• Female
• Folic Acid Antagonists (administration & dosage, adverse effects)
• Folic Acid Deficiency (chemically induced, prevention & control)
• Humans
• Infusions, Intravenous
• Methotrexate (administration & dosage, adverse effects)
• Pregnancy
• Pregnancy, Ectopic (blood, drug therapy)
• Time Factors
• Treatment Outcome